

## **Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018**

[Click to Tweet](#)

February 28, 2018

Boston, MA – [Flex Pharma, Inc.](#) (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that it will report its financial results for the fourth quarter and year-ended December 31, 2017 on Wednesday, March 7, 2018 before the U.S. financial markets open. The Company will host a conference call and webcast at 9:00 a.m. ET to discuss fourth quarter and full year 2017 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).

A live webcast may be accessed in the Investors section of the Company's website at [www.flex-pharma.com](http://www.flex-pharma.com). Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma's website for three months.

### **About Flex Pharma**

Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The Company's lead candidate, FLX-787, is being developed under Fast Track designation for the treatment of severe muscle cramps associated with ALS. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Christoph Westphal, M.D., Ph.D.

###

Contact:  
Elizabeth Woo  
SVP, Investor Relations & Corporate Communications  
Flex Pharma, Inc.  
[irdept@flex-pharma.com](mailto:irdept@flex-pharma.com)  
617-874-1829